A Phase 1 interventional study of Stiripentol capsule (Diacomit®) and Stiripentol oral suspension (Diacomit®) in Dravet Syndrome, Epilepsy and Childhood, sponsored by Biocodex. Completed at 2 sites in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Biocodex · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Epilepsies, Myoclonic with a site in France — 4 open to participants now, 8 under way, 3 of them phase 3. Epilepsies, Myoclonic · France.
Among the 18 studies in Epilepsies, Myoclonic with a site in France, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2025, is the only one in phase 1, and was the 18th registered.
92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.
Browse Epilepsies, Myoclonic studies →4 of the 18 studies in Epilepsies, Myoclonic with a site in France are open now. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 18–60 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages up to 15
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 6 mo–21 yrs
Longboard Pharmaceuticals · Sites in France, United States, Australia and 14 more countries
Ages 2–66
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 31 across 56 interventional studies indexed under Epilepsies, Myoclonic.
Median enrollment 144 across the 13 interventional studies, 92 across the 5 observational. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 18 have an industry lead sponsor. The 10 most frequent:
Biocodex is the lead sponsor of 19 studies on the registry; 6 are open to participants now.
Biocodex has 2 studies filed under Epilepsies, Myoclonic — fewer than ten, so there is no comparison to draw.
4 of the studies in Epilepsies, Myoclonic with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT06872125Phase 3Stoke Therapeutics, IncA Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | 2027-03 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT05373719Loulou FoundationObservational Study in Patients With Cyclin-dependent Kinase-like 5 Deficiency Disorder | 2027-01-20 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies in Epilepsies, Myoclonic with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase I, open-label, randomized, single-center, two-way cross-over study evaluating the relative bioavailability, pharmacokinetics, safety, and palatability of two formulations of stiripentol (Diacomit®), indicated in Dravet syndrome. The investigational products are 500 mg capsules (reference) and a 50 mg/mL oral suspension (test).
The primary objective is to compare the relative bioavailability of the two formulations after a single 1,000 mg oral dose under fed conditions, based on Cmax, AUC0-t, and AUC0-∞. Secondary objectives include other PK parameters (tmax, tlag, ke, t1/2) and characterization of metabolites MIa and MIb. Palatability of the suspension will be assessed by questionnaire.
Safety evaluation will include adverse events, laboratory tests, ECGs, urinalysis, drug and alcohol screening, serology, and vital signs.
Twenty-four healthy volunteers (18-50 years) will be enrolled. Eligibility: BMI 18-30 kg/m², weight ≥50 kg, normal ECG and labs, and informed consent. Women of childbearing potential must use effective contraception and test negative for pregnancy. Exclusions: significant disease, recent surgery or blood donation, hypersensitivity, difficulty swallowing, use of CYP modulators (e.g., carbamazepine, grapefruit, herbal products), drug or alcohol abuse, smoking >5 cigarettes/day, or inability to follow dietary restrictions. Subjects testing positive for HIV, HBV, HCV, or drugs of abuse will also be excluded.
Each participant will attend a screening visit within 28 days before dosing, then two 3-day hospitalizations separated by a 7-15-day washout. On Day 1 of each period, they will receive either two capsules (1,000 mg) or 20 mL suspension (1,000 mg). Blood will be collected at 36 timepoints (≈180 mL total) for PK assessment.
The total study duration per subject is about seven weeks, including screening, hospitalization, dosing, washout, and follow-up. Treatment consists of one dosing day per period.
Sample size was based on prior data: 21 pairs provide 80% power for bioequivalence within 0.80-1.25 bounds; 24 subjects will be recruited to account for dropouts. Analyses will include the Safety Set, PK Concentrations Set, and PK Analysis Set.
This trial aims to establish whether the oral suspension provides a PK profile comparable to capsules, while generating safety, tolerability, and palatability data to support a more convenient formulation for Dravet syndrome patients.
Stiripentol (Diacomit®) is currently marketed in two dosage forms: capsules (250 and 500 mg) and powder for oral suspension in sachets (250 and 500 mg). The powder formulation was developed for patients unable to swallow capsules. A previous study in healthy volunteers demonstrated that the capsule and sachet formulations were bioequivalent in terms of AUC but not Cmax. The Cmax of the sachet formulation was approximately 23% higher than that of the capsule, outside the accepted bioequivalence range. As a result, clinical supervision is recommended when switching between capsule and sachet formulations.
According to the European Summary of Product Characteristics (SmPC), stiripentol dosage escalation should be gradual, starting at 20 mg/kg/day and increasing stepwise depending on age. Dravet syndrome typically begins in infancy, and early initiation of antiepileptic treatment is recommended. A new oral suspension formulation (50 mg/mL) has been developed to facilitate flexible dose adjustments and accurate administration in pediatric patients, especially infants, where precise titration is essential.
This clinical study aims to compare the relative bioavailability of the new oral suspension (test formulation) to the capsule (reference formulation) after a single 1,000 mg dose under fed conditions. In addition to pharmacokinetic endpoints, safety, tolerability, and palatability will be assessed in healthy volunteers. The results will provide critical information on whether the new suspension offers a pharmacokinetic profile comparable to the capsule while improving dosing flexibility and patient convenience in clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to Sequence A will receive a single oral dose of 1,000 mg stiripentol (2 × 500 mg capsules, Diacomit®) at the end of breakfast under fed conditions in Period 1, followed by a single oral dose of 1,000 mg stiripentol (20 mL oral suspension, 50 mg/mL, Diacomit®) in Period 2 after a 7-15 day
Drug: Stiripentol capsule (Diacomit®) · Drug: Stiripentol oral suspension (Diacomit®)
Subjects randomized to Sequence B will receive a single oral dose of 1,000 mg stiripentol (20 mL oral suspension, 50 mg/mL, Diacomit®) at the end of breakfast under fed conditions in Period 1, followed by a single oral dose of 1,000 mg stiripentol (2 × 500 mg capsules, Diacomit®) in Period 2 after a 7-15 day washout.
Drug: Stiripentol capsule (Diacomit®) · Drug: Stiripentol oral suspension (Diacomit®)
Single oral administration of 1,000 mg stiripentol (2 × 500 mg capsules) at the end of breakfast.
Also known as: Stiripentol 500 mg capsule, Diacomit® capsule
Single oral administration of 1,000 mg stiripentol (20 mL oral suspension, 50 mg/mL) at the end of breakfast.
Also known as: Stiripentol 50 mg/mL suspension, Diacomit® oral suspension
Relative bioavailability of stiripentol oral suspension (50 mg/mL) vs capsule (500 mg) after a single 1,000 mg oral dose with food, assessed by PK parameters Cmax, AUC0-t, and AUC0-∞ using plasma LC-MS.
The relative bioavailability of stiripentol oral suspension (50 mg/mL) versus capsule (500 mg) after a single 1,000 mg oral dose under fed conditions. It will be assessed by calculating geometric mean ratios with 90% confidence intervals for the main pharmacokinetic parameters: maximum observed plasma concentration (Cmax), area under the concentration-time curve from time zero to the last measurable concentration (AUC0-t), and area under the concentration-time curve extrapolated to infinity (AUC0-∞). Plasma concentrations of stiripentol will be measured using validated liquid chromatography-mass spectrometry (LC-MS) methods to ensure accuracy and reliability of the pharmacokinetic evaluation.
Time frame: Up to 36 hours post-dose (per period)
Other PK parameters of stiripentol
Time to maximum concentration (tmax)
Time frame: Up to 36 hours post-dose (per period).
Safety and tolerability of stiripentol
Number, nature, incidence, seriousness, severity, and resolution of adverse events following single-dose administration.
Time frame: From dosing to end of study (~7 weeks per participant).
Palatability of stiripentol oral suspension
Assessed using a self-administered palatability questionnaire completed 20 minutes after administration of the oral suspension
Time frame: 20 minutes after administration of the oral suspension
Other PK parameters of stiripentol
Time before start of absorption (tlag)
Time frame: Up to 36 hours post-dose (per period)
Other PK parameters of stiripentol
Elimination rate constant (ke)
Time frame: Up to 36 hours post-dose (per period)
Other PK parameters of stiripentol
Terminal half-life (t1/2)
Time frame: Up to 36 hours post-dose (per period)
PK parameters of stiripentol metabolites (MIa, MIb)
Maximum concentration (Cmax)
Time frame: Up to 36 hours post-dose (per period)
PK parameters of stiripentol metabolites (MIa, MIb)
Area under the curve from time 0 (pre-dose) to the last measurable concentration (AUC0-t)
Time frame: Up to 36 hours post-dose (per period)
PK parameters of stiripentol metabolites (MIa, MIb)
Area under the curve from time 0 (pre-dose) to infinity (AUC0-∞)
Time frame: Up to 36 hours post-dose (per period)
PK parameters of stiripentol metabolites (MIa, MIb)
Time of occurrence of maximum concentration (tmax)
Time frame: Up to 36 hours post-dose (per period)
PK parameters of stiripentol metabolites (MIa, MIb)
Elimination rate constant (ke)
Time frame: Up to 36 hours post-dose (per period)
PK parameters of stiripentol metabolites (MIa, MIb)
Apparent terminal elimination half-life (t1/2) measured from plasma concentrations using Liquid chromatography-mass spectrometry (LC-MS)
Time frame: Up to 36 hours post-dose (per period)
Ran from Jun 2025 to primary completion in Aug 2025, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stiripentol
Biocodex